Equities research analysts predict that Kamada Ltd. (NASDAQ:KMDA) will report sales of $24.84 million for the current quarter, according to Zacks. Two analysts have made estimates for Kamada’s earnings, with the highest sales estimate coming in at $25.18 million and the lowest estimate coming in at $24.50 million. Kamada reported sales of $19.37 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 28.2%. The firm is expected to announce its next earnings report on Thursday, November 9th.
On average, analysts expect that Kamada will report full year sales of $24.84 million for the current year. For the next financial year, analysts expect that the business will post sales of $126.66 million per share, with estimates ranging from $120.80 million to $132.51 million. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that cover Kamada.
Kamada (NASDAQ:KMDA) last announced its quarterly earnings data on Tuesday, August 1st. The biotechnology company reported $0.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.12 by $0.01. Kamada had a negative return on equity of 2.94% and a negative net margin of 2.24%. The company had revenue of $32.55 million for the quarter, compared to analysts’ expectations of $33.30 million. During the same quarter in the prior year, the firm earned ($0.04) earnings per share. Kamada’s revenue was up 70.7% compared to the same quarter last year.
A number of brokerages have issued reports on KMDA. Zacks Investment Research raised Kamada from a “sell” rating to a “hold” rating in a research report on Wednesday, October 25th. ValuEngine lowered Kamada from a “hold” rating to a “sell” rating in a research report on Friday, September 1st. Jefferies Group LLC reissued a “buy” rating and issued a $7.00 target price (down previously from $9.00) on shares of Kamada in a research report on Wednesday, August 2nd. Finally, TheStreet lowered Kamada from a “c-” rating to a “d+” rating in a research report on Tuesday, August 1st. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating to the company. Kamada has a consensus rating of “Hold” and a consensus target price of $8.50.
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Edmond DE Rothschild Holding S.A. raised its position in Kamada by 10.5% in the second quarter. Edmond DE Rothschild Holding S.A. now owns 42,200 shares of the biotechnology company’s stock valued at $251,000 after purchasing an additional 4,000 shares during the period. Vanguard Group Inc. raised its position in Kamada by 6.5% in the second quarter. Vanguard Group Inc. now owns 468,390 shares of the biotechnology company’s stock valued at $2,810,000 after purchasing an additional 28,382 shares during the period. Renaissance Technologies LLC raised its position in Kamada by 16.7% in the first quarter. Renaissance Technologies LLC now owns 264,800 shares of the biotechnology company’s stock valued at $1,801,000 after purchasing an additional 37,800 shares during the period. Navellier & Associates Inc purchased a new stake in Kamada in the second quarter valued at approximately $303,000. Finally, Paulson & CO. Inc. raised its position in Kamada by 8.2% in the second quarter. Paulson & CO. Inc. now owns 790,800 shares of the biotechnology company’s stock valued at $4,745,000 after purchasing an additional 60,000 shares during the period. 7.25% of the stock is currently owned by institutional investors.
Kamada (KMDA) opened at 5.05 on Tuesday. The company’s market cap is $188.87 million. The company has a 50-day moving average price of $4.81 and a 200 day moving average price of $5.76. Kamada has a 52 week low of $3.75 and a 52 week high of $8.61.
Kamada Company Profile
Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Kamada Ltd.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Kamada Ltd. and related companies.